Subjects: Antibodies, Monoclonal, Humanized -- adverse effects and Complement C1 Inhibitor Protein -- adverse effects / Publication Year: 2018 - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Antibodies, Monoclonal, Humanized -- adverse effects ✖ Subjects Complement C1 Inhibitor Protein -- adverse effects ✖ Publication Year 2018 ✖

1. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):: Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States